ReviewFrontiers in immunology2020
Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD.Respiratory research · 2024Trial
- IRF7 deficiency in myeloid cells results in increased disease severity and death during alphavirus encephalomyelitis despite intact expression of type I interferons.Journal of neuroinflammation · 2026Article
- Locus-Specific Convergent Evolution and Interchromosomal Rearrangements Contribute to the Diversification of Amniote Type I Interferons.Evolutionary applications · 2026Article
- Interferon-β Modulates Early Viral Replication Kinetics and Innate Responses to Non-Fatal Alphavirus Encephalomyelitis.Pathogens (Basel, Switzerland) · 2026Article
- Cell-Intrinsic Type I Interferon Signaling as a Pleiotropic Orchestrator of CD4 T Cell Immunity.Biomolecules · 2026Review
- IFNIKB: a type I interferon database for antitumuor immunity studies.Database : the journal of biological databases and curation · 2026Article
- Deciphering TLR and JAK/STAT pathways: genetic variants and targeted therapies in COVID-19.Molecular biology reports · 2025Review
- Feasibility of Using a Type I IFN-Based Non-Animal Approach to Predict Vaccine Efficacy and Safety Profiles.Vaccines · 2024Review
- Type I interferon pathway genetic variants in severe COVID-19.Virus research · 2024Review
- Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on Highly Invasive Human T24 Bladder Cancer Cells.International journal of molecular sciences · 2024Article
- Feasibility of home administration of nebulised interferon ß-1a (SNG001) for COVID-19: a remote study.BJGP open · 2023Article
- Combined therapy of local recombinant human interferon α1b injection and acupuncture on verruca vulgaris: a retrospective study.Archives of dermatological research · 2023Article
- Immunomodulatory Role of Interferons in Viral and Bacterial Infections.International journal of molecular sciences · 2023Review
- STAM and Hrs interact sequentially with IFN-α Receptor to control spatiotemporal JAK-STAT endosomal activation.Nature cell biology · 2023Article
- Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study.ERJ open research · 2023Article
- Inborn Errors of Immunity Predisposing to Herpes Simplex Virus Infections of the Central Nervous System.Pathogens (Basel, Switzerland) · 2023Review
- Effect of regulatory cell death on the occurrence and development of head and neck squamous cell carcinoma.Biomarker research · 2023Review
- Endothelial type I interferon response and brain diseases: identifying STING as a therapeutic target.Frontiers in cell and developmental biology · 2023Review
- Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis.Journal of virology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Type I interferons (IFNs) are critical effector cytokines of the immune system and were originally known for their important role in protecting against viral infections; however, they have more recently been shown to play protective or detrimental roles in many disease states. Type I IFNs consist of IFNα, IFNβ, IFNϵ, IFNκ, IFNω, and a few others, and they all signal through a shared receptor to exert a wide range of biological activities, including antiviral, antiproliferative, proapoptotic, and immunomodulatory effects. Though the individual type I IFN subtypes possess overlapping functions, there is growing appreciation that they also have unique properties. In this review, we summarize some of the mechanisms underlying differential expression of and signaling by type I IFNs, and we discuss examples of differential functions of IFNα and IFNβ in models of infectious disease, cancer, and autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.